Palvella Therapeutics, Inc. (PVLA) NASDAQ
112.50
-1.41(-1.24%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
112.50
-1.41(-1.24%)
Currency In USD
| Previous Close | 113.91 |
| Open | 112.54 |
| Day High | 115.57 |
| Day Low | 109.36 |
| 52-Week High | 151.18 |
| 52-Week Low | 18.23 |
| Volume | 224,493 |
| Average Volume | 307,133 |
| Market Cap | 1.33B |
| PE | -38.53 |
| EPS | -2.92 |
| Moving Average 50 Days | 103.28 |
| Moving Average 200 Days | 71.39 |
| Change | -1.41 |
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
GlobeNewswire Inc.
Mar 10, 2026 11:30 AM GMT
BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers, and healthcare professionals Campaign developed and launched in close collaboration with leading nonprofit organizations, including the Consortium of iNvestigators
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Mar 02, 2026 12:30 PM GMT
WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, r
Palvella Therapeutics Announces Pricing of Upsized Public Offering
GlobeNewswire Inc.
Feb 26, 2026 12:57 AM GMT
WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, ra